'Substantially increased' risk of intracranial haemorrhage with higher-dose rivaroxaban

NOACs compared with aspirin

Higher doses of rivaroxaban increase patients' risk of intracranial haemorrhage compared with aspirin, whereas lower doses of rivaroxaban and apixaban do not, according to a systematic review and meta-analysis.